Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alatrofloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 1/20 | 0.69 |
| ▸ | FLT4 | P35916 | 1/20 | 0.69 |
| ▸ | GSK3B | P49841 | 1/20 | 0.69 |
| ▸ | RARB | P10826 | 1/20 | 0.69 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.69 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 5/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | HPGD | P15428 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | XBP1 | P17861 | 1/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.68 |
| ▸ | RELA | Q04206 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | DPP4 | P27487 | 6/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alatrofloxacin SCHEMBL7616277 | 1.00 | EPHA2 (0.69) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Alatrofloxacin SCHEMBL29493446 | 1.00 | EPHA2 (0.69) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Alatrofloxacin SCHEMBL7618000 | 1.00 | EPHA2 (0.69) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Alatrofloxacin SCHEMBL7101443 | 1.00 | EPHA2 (0.69) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| SCHEMBL6848316 | 0.97 | EPHA2 (0.65) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Alatrofloxacin SCHEMBL28214885 | 0.97 | EPHA2 (0.75) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Alatrofloxacin SCHEMBL29389843 | 0.97 | LMNA (0.73) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Alatrofloxacin SCHEMBL41134 | 0.97 | LMNA (0.73) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Alatrofloxacin SCHEMBL8186971 | 0.97 | LMNA (0.73) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| SCHEMBL9735079 | 0.95 | EPHA2 (0.74) | EPHA2FLT4GSK3BRARBTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2461 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624057-B2 | Bisphosphonate quinolone conjugates and uses thereof | BIOVINC, LLC (US) | 2026-05-12 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2025-11-06 | — | — | US | claimed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| WO-2025111413-A1 | TREATMENT FOR SKIN DISORDERS | Mycotechnology, Inc. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2025093735-A2 | AGENTS FOR USE IN THE TREATMENT OF TAUOPATHIES | DRUG TARGET IP B.V. (NL) | 2025-05-08 | — | — | WO | claimed |
| US-12274830-B2 | Nitric oxide inhalation therapy for infants with bronchiolitis | BEYOND AIR LTD (IL) | 2025-04-15 | — | — | US | claimed |
| WO-2024240173-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2024-11-28 | — | — | WO | claimed |
| EP-1165048-A1 | COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF IONIZABLE HYDROPHOBIC THERAPEUTIC AGENTS | Lipocine, Inc. (US) | 2002-01-02 | — | — | EP | claimed |
| WO-2001098297-A2 | A THIAZINE OXAZOLIDINONE | PHARMACIA & UP JOHN COMPANY (US) | 2001-12-27 | — | — | WO | claimed |
| US-6309663-B1 | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents | LIPOCINE INC. | 2001-10-30 | — | — | US | claimed |
| EP-1121933-A1 | Premixed alatrofloxacin injectable compositions | Pfizer Products Inc. (US) | 2001-08-08 | — | — | EP | claimed |
| US-6248363-B1 | Improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutraceuticals, cosmeceuticals and diagnostic agents | LIPOCINE, INC. | 2001-06-19 | — | — | US | claimed |
| WO-2001037808-A1 | SOLID CARRIERS FOR IMPROVED DELIVERY OF ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS | LIPOCINE, INC. (US) | 2001-05-31 | — | — | WO | claimed |
| WO-2001028555-A1 | EMULSION COMPOSITIONS FOR POLYFUNCTIONAL ACTIVE INGREDIENTS | LIPOCINE, INC. (US) | 2001-04-26 | — | — | WO | claimed |
| WO-2001012155-A1 | COMPOSITIONS AND METHODS FOR ENHANCED ABSORPTION OF HYDROPHILIC THERAPEUTIC AGENTS | LIPOCINE, INC. (US) | 2001-02-22 | — | — | WO | claimed |
| WO-2000059475-A1 | COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF IONIZABLE HYDROPHOBIC THERAPEUTIC AGENTS | LIPOCINE, INC. (US) | 2000-10-12 | — | — | WO | claimed |
| EP-0982031-A2 | Antifungal compositions comprising voriconazole and trovafloxacin or prodrugs thereof | PFIZER INC. (US) | 2000-03-01 | — | — | EP | claimed |